Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
On November 1, the Centers for Medicare & Medicaid Services (CMS) released its final rule for reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS) in 2020. ASCO is still analyzing the rule and will provide in-depth analysis for members as soon as possible.
Massive shifts in the health care landscape, prompted in large part by the transition to value-based care, are creating new challenges and exacerbating existing pressures throughout the oncology ecosystem.
Access a new toolkit developed by the ASCO Research Community Forum to offer resources to help sites prepare for an FDA audit. Complete a brief demographic survey for access.
Plan to attend a free upcoming webinar taking place December 11 from 3:00 - 4:00 PM ET. In this webinar, a cancer survivor, community oncologist, and research nurse will share their perspectives on the benefits and challenges of being involved in clinical trials, especially in the community setting. They will offer practical strategies and resources to ensure clinical trial access and participation, including how to effectively discuss clinical trials with your patients and colleagues.
Only one in four Americans say they incorporate cancer prevention into their daily lives, according to ASCO’s third annual National Cancer Opinion Survey. The survey also found low levels of awareness of known cancer risk factors such as alcohol and obesity, and misconceptions among a substantial minority of Americans that artificial sweeteners and cell phones cause cancer in humans. The survey also revealed that nearly one in four young people believes e-cigarettes are harmless and not addictive.
On October 23, 2019, the Food and Drug Administration approved niraparib (ZEJULA®, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.
CMS recently posted five Continuing Medical Education (CME) modules on Alternative Payment Models (APMs). Access them now by logging into the Medicare Learning Network Learning Management System.
On October 17, 2019, CMS posted a supplement to the ICD-10-CM Official Coding Guidelines for encounters related to e-cigarette, or vaping, product use. Please visit the 2020 ICD-10-CM webpage for more information.